PHARMAC’s decision over diabetes drugs could see up to 140,000 ‘miss out’, doctor says


11 June 2021 - Dr John Baker​, the chair of the Diabetes Foundation Aotearoa, says that has to change and highlights the shortcomings of the government drug funding agency’s funding model.

His comments follow the release of documents released under the Official Information Act by PHARMAC on its decision late last year to fund empagliflozin and dulaglutide, and feedback from people in the health sector.

Read Stuff article

Michael Wonder

Posted by:

Michael Wonder